Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy
OXFORD, United Kingdom, June 12, 2023 -- Vaccitech plc , a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics for the treatment of... | June 12, 2023
Source: marketscreener.com